Tags

Type your tag names separated by a space and hit enter

Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.).
Lancet. 1979 Apr 14; 1(8120):803-5.Lct

Abstract

14 patients with osteolytic bone disease due to breast cancer or myeloma, 7 of whom had hypercalcaemia, received oral treatment with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Serum-calcium dropped to low normal values in all 14 patients, accompanied by a decrease in urine calcium and hydroxyproline excretion-rate. The results show that A.P.D. may inhibit tumour-induced osteolysis.

Links

Publisher Full Text

Authors

van Breukelen FJ
No affiliation info available
Bijvoet OL
No affiliation info available
van Oosterom AT
No affiliation info available

MeSH

Bone ResorptionBreast NeoplasmsCalciumCreatinineDiphosphonatesFemaleHumansHydroxyprolineHypercalcemiaMultiple MyelomaOsteolysisPropanolamines

Pub Type(s)

Journal Article

Language

eng

PubMed ID

86043

Citation

van Breukelen, F J., et al. "Inhibition of Osteolytic Bone Lesions By (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.)." Lancet (London, England), vol. 1, no. 8120, 1979, pp. 803-5.
van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979;1(8120):803-5.
van Breukelen, F. J., Bijvoet, O. L., & van Oosterom, A. T. (1979). Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet (London, England), 1(8120), 803-5.
van Breukelen FJ, Bijvoet OL, van Oosterom AT. Inhibition of Osteolytic Bone Lesions By (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Lancet. 1979 Apr 14;1(8120):803-5. PubMed PMID: 86043.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Inhibition of osteolytic bone lesions by (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). AU - van Breukelen,F J, AU - Bijvoet,O L, AU - van Oosterom,A T, PY - 1979/4/14/pubmed PY - 1979/4/14/medline PY - 1979/4/14/entrez SP - 803 EP - 5 JF - Lancet (London, England) JO - Lancet VL - 1 IS - 8120 N2 - 14 patients with osteolytic bone disease due to breast cancer or myeloma, 7 of whom had hypercalcaemia, received oral treatment with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (A.P.D.). Serum-calcium dropped to low normal values in all 14 patients, accompanied by a decrease in urine calcium and hydroxyproline excretion-rate. The results show that A.P.D. may inhibit tumour-induced osteolysis. SN - 0140-6736 UR - https://www.unboundmedicine.com/medline/citation/86043/Inhibition_of_osteolytic_bone_lesions_by__3_amino_1_hydroxypropylidene__1_1_bisphosphonate__A_P_D___ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0140-6736(79)91319-9 DB - PRIME DP - Unbound Medicine ER -